Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $43,114.75 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 12,425 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $43,114.75. Following the transaction, the insider now owns 194,375 shares in the company, valued at $674,481.25. This trade represents a 6.01 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Amylyx Pharmaceuticals Stock Performance

Shares of Amylyx Pharmaceuticals stock opened at $3.43 on Friday. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27. The business’s 50 day simple moving average is $3.55 and its 200 day simple moving average is $4.05. The firm has a market cap of $303.90 million, a PE ratio of -0.90 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. As a group, equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMLX. Boxer Capital Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $6,615,000. Bank of America Corp DE grew its stake in Amylyx Pharmaceuticals by 165.9% in the fourth quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock valued at $9,171,000 after purchasing an additional 1,513,748 shares in the last quarter. Walleye Capital LLC increased its position in shares of Amylyx Pharmaceuticals by 986.5% during the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after purchasing an additional 608,874 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Amylyx Pharmaceuticals by 862.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company’s stock worth $1,786,000 after purchasing an additional 423,316 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 122.4% in the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company’s stock valued at $2,893,000 after buying an additional 421,302 shares during the last quarter. 95.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.